Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH, reported preliminary 2025 financial results showing €99.3 million in cash and equivalents plus €131.6 million in short-term deposits. The company generated €4.5 million in revenue and consumed €104.6 million in operating cash flows. Following a $172.5 million US public offering and structured financing, Inventiva estimates its liquidity will support operations until mid-Q1 2027, or mid-Q3 2027 if warrant tranches are fully exercised.

Inventiva, a clinical-stage biopharmaceutical company, reported preliminary 2025 financial results showing cash and cash equivalents of €99.3 million plus €131.6 million in short-term deposits. The company generated €4.5 million in revenues and used €104.6 million in operating activities. Following a U.S. public offering raising $172.5 million and structured financing, Inventiva estimates cash runway until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants are fully exercised. R&D expenses focused on lanifibranor development for MASH treatment amounted to €86.9 million.

Inventiva announced that its CEO Andrew Obenshain will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. The company will also hold individual meetings during the conference. Inventiva is developing lanifibranor, a small molecule oral therapy currently in Phase 3 clinical trials for the treatment of MASH (metabolic dysfunction-associated steatohepatitis).

Inventiva announced that CEO Andrew Obenshain will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, in New York City. The company will also hold one-on-one meetings during the conference. Inventiva is a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, currently evaluating lanifibranor in the NATiV3 Phase 3 clinical trial.

Inventiva held its Combined Shareholders' Meeting on November 27, 2025, where most resolutions were adopted, except for the 5th resolution regarding share capital increases for a company savings plan.

Inventiva held its Mixed Shareholders Meeting on November 27, 2025, where most resolutions were adopted, except for the 5th resolution related to capital increases for employee savings plans.

Inventiva completed a public offering of 38,961,038 American Depositary Shares on Nasdaq, with underwriters fully exercising their option to purchase additional shares, bringing total proceeds to approximately $172.5 million.

Inventiva reported stabilization activities following its recent public offering of 38,961,038 American Depositary Shares on the Nasdaq Global Market, with Piper Sandler acting as the stabilization agent.

Inventiva reported €97.6 million in cash and cash equivalents as of September 30, 2025, with revenues of €4.5 million for the first nine months of 2025. The company expects its cash runway to extend until the end of Q1 2027, supported by a recent public offering that raised approximately €149 million.

Inventiva reports a cash and cash equivalents position of €97.6 million as of September 30, 2025, with revenues of €4.5 million for the first nine months. The company expects its cash resources to fund operations until the end of Q1 2027, potentially extending to mid-Q3 2027 if certain warrants are exercised.

Inventiva, a biopharmaceutical company, will temporarily suspend trading on Euronext Paris for a public offering of American Depositary Shares in the United States, with trading expected to resume around 15:30 CET.

Inventiva, a clinical-stage biopharmaceutical company, temporarily halted trading of its ordinary shares on Euronext Paris in preparation for a public offering of American Depositary Shares in the United States.